Oseltamivir reduces ICU risk in children

A nationwide study published in JAMA Pediatrics on August 10, 2026, found that children hospitalized with laboratory-confirmed influenza who received the antiviral oseltamivir were 31% less likely to be admitted to an intensive care unit (ICU) and had shorter hospital stays compared to those who did not receive the drug. The study, led by researchers at the University of Colorado Anschutz, analyzed over 7,000 pediatric hospitalizations across 13 states over eight influenza seasons (2014-2023) using data from the CDC-supported United States — FluSurv-NET surveillance network. The findings reinforce national guidelines recommending antiviral treatment for hospitalized children with suspected or confirmed influenza, even when treatment is initiated more than 48 hours after symptom onset. The study is observational, so causality cannot be established, and residual confounding may exist. The authors note that antiviral use among hospitalized children has declined despite recommendations, and the results support prompt treatment to reduce severe outcomes.